Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Axovant licenses worldwide rights to Benitec's BB301 and five other CNS gene therapy programs

Executive Summary

Axovant Sciences Ltd. licensed exclusive worldwide rights to Benitec Biopharma Ltd.'s preclinical oculopharyngeal muscular dystrophy (OPMD) candidate BB301, which Axovant has renamed AXO-AAV-OPMD. The two will also collaborate on five neurology programs incorporating Benitec's DNA-directed RNA interference (ddRNAi) platform.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies